PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
1. PMVP's Phase 2 trial shows 33% overall response rate in various cancers. 2. Ovarian cancer cohort demonstrated 43% response rate with durable outcomes. 3. NDA for ovarian cancer expected by Q1 2027, enhancing market positioning. 4. Investor webinar scheduled for today to discuss interim results and regulatory plans. 5. Rezatapopt is a first-in-class therapy targeting p53 mutations in solid tumors.